Stock listing

NYSE American:SER Serina Therapeutics, Inc. Stock

Home listing (NYSE American) of Serina Therapeutics, Inc.

Follow Serina Therapeutics, Inc. into a list and get an email when it puts out news.

Share price · AMEX:SER

$1.12 USD -0.23 (-17.0%)

Close on Nov 20, 2026

Past year -70.2% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$1.06 – $1.26 USDNov 20, 2026
Volume
62,151 sharesNov 20, 2026
Market cap
$28.45M USDAt the close on Nov 20, 2026 · price × 25.40M shares outstanding
52-week range
$1.06 – $4.26 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$134,681 USDMedian day 31,000 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Serina Therapeutics, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NYSE American:SER · Home$1.12 USD-0.23 (-17.0%)62,151$1.16$1.26$1.06$1.35Close on Nov 20, 2026
Frankfurt:2BO€1.06 EUR-0.14 (-11.7%)—€1.07€1.07€1.06€1.20Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · AMEX:SER · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$1.12-0.23-17.0%$1.16$1.26$1.0662,151
$1.35-0.015-1.1%$1.46$1.46$1.3512,204
$1.365-0.055-3.9%$1.32$1.41$1.3028,434
$1.42+0.03+2.2%$1.41$1.45$1.3456,667
$1.39-0.02-1.4%$1.35$1.52$1.3510,774
$1.41-0.09-6.0%$1.50$1.555$1.3928,386
$1.50+0.07+4.9%$1.46$1.614$1.4217,879
$1.430.000.0%$1.43$1.53$1.3944,578
$1.43+0.05+3.6%$1.29$1.54$1.2991,788
$1.38-0.27-16.4%$1.65$1.713$1.14491,717
$1.65-0.04-2.4%$1.68$1.709$1.61421,200
$1.69-0.14-7.7%$1.70$1.80$1.62639,627
$1.83-0.02-1.1%$1.79$1.85$1.6730,588
$1.85-0.09-4.6%$1.92$1.99$1.8537,818
$1.94+0.05+2.6%$1.47$2.55$1.47155,099
$1.89+0.25+15.2%$1.51$1.99$1.48560,508
$1.64-0.03-1.8%$1.28$1.70$1.2828,260
$1.67-0.04-2.3%$1.38$1.75$1.38172,032
$1.71+0.06+3.6%$1.63$1.75$1.58838,290
$1.65-0.11-6.3%$1.73$1.76$1.658,000
$1.76-0.01-0.6%$1.73$1.80$1.7251,300
$1.77+0.11+6.6%$1.67$1.78$1.6339,800
$1.66+0.01+0.6%$1.64$1.735$1.6342,100
$1.65-0.07-4.1%$1.75$1.81$1.6522,000
$1.72-0.07-3.9%$1.72$1.83$1.7215,700
$1.79+0.08+4.7%$1.71$1.94$1.7127,400
$1.71-0.11-6.0%$1.80$1.838$1.7146,300
$1.82-0.12-6.2%$1.92$1.974$1.7826,300
$1.94-0.06-3.0%$2.01$2.01$1.90132,200
$2.00-0.01-0.5%$1.99$2.05$1.9922,300
$2.010.000.0%$2.01$2.05$1.9959,300
$2.01-0.03-1.5%$2.04$2.08$2.0112,900
$2.040.000.0%$2.025$2.08$2.0168,719
$2.04+0.08+4.1%$2.10$2.10$1.96525,270
$1.96+0.01+0.5%$1.98$2.10$1.95215,200
$1.95-0.05-2.5%$1.96$2.06$1.9546,800
$2.00-0.08-3.8%$2.09$2.09$2.0010,800
$2.08+0.07+3.5%$1.97$2.13$1.9715,775
$2.01-0.08-3.8%$2.08$2.20$2.001,018,110
$2.09-0.05-2.3%$2.13$2.197$2.0928,400
$2.14-0.05-2.3%$2.19$2.298$2.1476,300
$2.19-0.12-5.2%$2.30$2.315$2.177,900
$2.310.000.0%$2.28$2.43$2.1623,800
$2.31+0.06+2.7%$2.15$2.371$2.0031,000
$2.25+0.03+1.4%$2.20$2.29$2.08765,100
$2.22+0.06+2.8%$2.26$2.31$2.1830,000
$2.16-0.19-8.1%$2.35$2.35$2.1621,500
$2.35-0.10-4.1%$2.46$2.47$2.2531,700
$2.45+0.23+10.4%$2.35$2.55$2.2874,400
$2.22-0.28-11.2%$2.41$2.54$2.2069,300
$2.50-0.07-2.7%$2.55$2.58$2.3668,800
$2.57+0.07+2.8%$2.75$2.78$2.35404,100
$2.50-0.23-8.4%$2.75$2.75$2.47542,300
$2.73+0.04+1.5%$2.70$2.74$2.51214,900
$2.69+0.07+2.7%$2.68$2.69$2.57518,000
$2.62+0.12+4.8%$2.50$2.67$2.4270,946
$2.50+0.08+3.3%$2.40$2.54$2.3832,637
$2.42-0.04-1.6%$2.40$2.50$2.3823,116
$2.46-0.06-2.4%$2.52$2.53$2.4133,800
$2.52-0.11-4.2%$2.61$2.643$2.5229,500
$2.63-0.07-2.6%$2.67$2.70$2.5615,500
$2.70+0.07+2.7%$2.73$2.80$2.5527,400
$2.63-0.24-8.4%$2.77$2.855$2.6336,100
$2.87+0.22+8.3%$2.67$2.87$2.61846,100
$2.65-0.07-2.6%$2.64$2.695$2.5624,800

Splits

1 split · AMEX:SER · every price before a split is adjusted for it

DayRatioWhat
1-for-35.7143Consolidation
Ticker
NYSE American:SER
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NYSE American
Currency
USD

What changed lately

Latest news

All Serina Therapeutics, Inc. news

Serina Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
13 in the last 12 months · 32 in all · newest Nov 12, 2026 · oldest 2025
Decks
14 decks · latest September 2026

Where Serina Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NYSE American:SER · Home listing · This pageNYSE AmericanUnited StatesUSD
Tradegate:2BOTradegateGermanyEUR
BOATS:SERBOATSUnited StatesUSD
gettex:2BOgettexGermanyEUR
Lang & Schwarz:A407RQLang & SchwarzGermanyEUR
Frankfurt:2BOFrankfurtGermanyEUR

Valuation

EV/sales 99.3× against a median of 1.2×: the highest of 3 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$12.42M USD
P/E
Loss
EV/sales
99.3×
EV/EBITDA
Negative EBITDA
Price/book
2.0×
Gross margin
Revenue too small
Operating margin
Revenue too small
Net margin
Revenue too small
Debt to equity
0.2×
Beta vs S&P 500
1.60

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Serina Therapeutics, Inc. · AMEX:SERUS$28.45MUS$12.42Mn/a99.3×n/a2.0×n/a0.2×1.60
NextCure, Inc. · NASDAQ:NXTCUS$29.53MUS$20.81Mn/an/an/a5.4×n/a0.0×1.85
NurExone Biologic Inc · TSXV:NRXUS$29.53MUS$28.52Mn/an/an/a23.3×n/a0.0×0.00
BioHarvest Sciences, Inc. · NASDAQ:BHSTUS$29.47MUS$34.54Mn/a1.0×n/a1.8×−34.7%1.0×0.43
Thiogenesis Therapeutics Corp · TSXV:TTIUS$29.28MUS$24.21Mn/an/an/a6.2×n/a0.0×0.37
NanoViricides, Inc. · AMEX:NNVCUS$29.11MUS$26.54Mn/an/an/a4.5×n/a0.0×1.82
Rein Therapeutics, Inc. · NASDAQ:RNTXUS$29.06M−US$6.43Mn/an/an/a0.6×n/a0.0×2.11
Nicox SA · EURONEXT:ALCOXUS$29.05MUS$25.67Mn/a1.4×n/a3.8×−14.4%0.4×n/a
ProMIS Neurosciences Inc. · NASDAQ:PMNUS$28.43M−US$15.68Mn/an/an/a0.7×n/a0.0×0.83
Entropy Neurodynamics Limited · ASX:ENPUS$28.12MUS$24.43Mn/an/an/a5.8×n/a0.0×n/a
Holy Stone Healthcare Co., Ltd. · TPEX:4194US$27.49MUS$25.08Mn/an/an/a7.3×n/a0.0×n/a
Median of the othersUS$29.09MUS$24.76M1.2×5.0×−24.5%0.0×0.83

Forecasts

1 strong buy · Analysts' consensus from EODHD, read Nov 21, 2026. Not 6ix's view and not investment advice.

Price target
9.50 USD · Analysts' mean
EPS, year to Dec 2026
-1.47 · 2 analysts
Revenue, year to Dec 2026
125K · 1 analyst

Team and board

Officers

OfficerRole
Steve LedgerCEO & Director
Greg CurhanCFO
Joshua ThomasVP, Head of Chemistry
Randall MoreadithChief Development Officer
Srini TenjarlaChief Technical Operations Officer

Board

DirectorRole
Gregory BaileyCo-Chairman
Simba GillExecutive Co-Chairman
Farrell SimonDirector
Jay VenkatesanDirector
Karen J. WilsonDirector
Richard MarshallDirector
Steve BrannanDirector
Steve LedgerCEO & Director

Events

Next results
Nov 26, 2026 (expected)
QuarterResultsShare move
Q2 2026Aug 13, 2026 · After close−1.8%
Q1 2026May 14, 2026 · After close−4.7%
Q4 2025Mar 30, 2026−14.5%
Q3 2025Nov 13, 2025 · Before open−2.5%
Q2 2025Aug 11, 2025 · After close+7.1%
Q1 2025May 8, 2025 · After close−2.0%
Q4 2024Mar 20, 2025 · Before open+2.5%
Q3 2024Nov 11, 2024 · Before open+20.9%
Q2 2024Aug 9, 2024 · After close−10.1%
Q1 2024May 14, 2024 · After close−4.4%
All 20 quarters
QuarterResultsShare move
Q4 2023Mar 22, 2024 · After close−3.3%
Q4 2022Mar 31, 2023−1.4%
Q3 2022Nov 10, 2022−5.4%
Q2 2022Aug 12, 2022−0.3%
Q1 2022May 13, 2022+0.1%
Q4 2021Mar 29, 2022+6.8%
Quarter to Sep 30, 2021Nov 12, 2021−1.1%
Quarter to Jun 30, 2021Aug 13, 2021−13.6%
Quarter to Mar 31, 2021May 17, 2021+2.5%
Quarter to Dec 31, 2020Mar 31, 2021+8.6%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (September 2026)Investor deck20 slidesSeptember 2026
Investor Presentation (July 2025)Investor deck22 slidesJul 29, 2025
BTIG Small Molecule Platform Presentation (July 2025)Conference21 slidesJuly 2025
4th LNP Formulation & Process Development Summit 2025Conference36 slidesApr 15, 2025
Investor Presentation (April 2025)Investor deck26 slidesApr 7, 2025
ACS – Division of Polymer Chemistry (March 2025)Conference36 slidesMar 24, 2025
Investor Presentation (January 2025)Investor deck25 slidesJan 6, 2025
3rd Immunogenicity & Toxicity Summit 2024Conference32 slidesDec 11, 2024
14th Injectables Summit (October 2024)Conference23 slidesOct 2, 2024
4th mRNA-based Therapeutics Summit 2024Conference34 slidesJul 29, 2024
All 14 decks
DeckKindSlidesDate
AgeX Therapeutics — Rodman & Renshaw Global Investment Conference 2019Conference33 slidesSep 9, 2019
2nd Neuroscience Innovation Forum 2019Conference27 slidesJan 6, 2019
PODD 2016Conference16 slides2016
Investor Presentation (April 2014)Investor deck18 slidesApril 2014

Open Decks

Financings

RaiseDate
At-the-market programme of common stock
Tranche closed: US$6 a share · JonesTrading Institutional Services LLC
Dealers: JonesTrading Institutional Services LLC (lead)
Nov 13, 2025
Financing agreement tranche
Tranche closed: US$5M raised · US$5.18 a share · Warrants at US$5.44
Buyers: Greg Bailey, MD (leads the up to $20 million financing)
Insiders: Financing led by Serina Board Director Greg Bailey, MD
Use of proceeds: Advance the planned registrational trial of SER-252 for advanced Parkinson's disease
Oct 6, 2025

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue130.0K56.0K3.15M34.0K144.0K361.0K1.73M1.40M1.40M1.67M
Cost of revenue85.0K194.0K40.0K13.0K19.0K26.0K244.0K364.0K168.0K911.0K
Gross profit45.0K-138.0K102.0K21.0K125.0K335.0K1.48M1.03M1.24M755.0K
Research and development13.2M7.48M2.39M1.02M1.46M3.71M5.90M5.83M5.78M7.87M
Selling, general and administrative11.0M9.62M3.89M1.29M1.30M
Operating income-24.0M-17.0M-3.13M-6.97M-7.93M-10.1M-12.6M-11.2M-6.66M-12.7M
Depreciation and amortization100.0K100.0K90.0K61.3K33.4K699.0K393.0K58.0K165.0K845.0K
EBITDA-23.9M-16.9M-3.04M-6.91M-7.90M-9.40M-12.2M-11.2M-6.50M-11.9M
Interest expense213.0K526.0K4.90M3.33M1.10M404.0K12.0K25.0K
Income before tax-19.2M-11.2M5.27M10.5M8.70M-11.1M-12.2M-7.73M-6.64M-17.4M
Income tax18.0K00-250.0K3.09K-150.0K148.0K-229.0K-57.0K-1.86M
Net income-19.2M-11.1M5.27M-10.5M-8.68M-10.9M-12.2M-7.50M-6.58M-15.5M
Earnings per share, basic-1.91-1.512.36-9.70-0.23-0.29-0.33-0.21-0.21-15.21
Earnings per share, diluted-1.91-1.510.73-9.70-0.23-0.29-0.33-0.21-0.21

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents3.06M3.67M7.62M645.0K584.0K527.0K2.35M6.71M7.38M259.0K
Short-term investments1.72M00996.4K
Receivables57.0K4.00K25.0K326.0K363.0K131.0K107.0K308.0K
Inventory-1.79M-1.61M
Current assets6.08M5.68M7.62M2.45M2.23M2.28M4.05M7.85M7.59M688.0K
Property, plant and equipment465.0K501.0K573.0K1.13M90.0K129.0K
Total assets6.95M6.72M8.97M3.24M3.15M3.92M7.44M10.7M9.63M3.22M
Accounts payable1.93M744.0K580.0K568.0K193.0K761.0K420.0K150.0K75.0K261.0K
Current liabilities3.56M2.37M1.41M10.1M8.97M5.36M3.30M2.44M1.31M25.6M
Long-term debt2.95M02.98M1.62M
Total debt196.0K268.0K3.44M18.1M13.2M6.30M1.96M
Total liabilities6.99M6.22M4.86M20.6M15.0M9.32M4.83M2.44M1.31M25.6M
Shareholders' equity-37.0K641.0K-32.3M-37.8M-11.8M-5.12M2.22M7.45M7.28M-23.4M
Shares outstanding10.8M9.42M2.41M1.08M37.9M37.7M37.6M35.8M33.8M1.02M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-18.0M-17.1M-2.48M-5.94M-7.86M-7.82M-10.2M-8.00M-6.29M-8.43M
Capital spending-59.0K-22.0K-504.0K-9.68K-108.4K-20.0K-641.0K-21.0K-1.00K-23.0K
Free cash flow-18.0M-17.2M-2.98M-2.09M-2.36M-7.84M-10.8M-8.02M-6.29M-8.45M
Cash from investing-59.0K-22.0K-504.0K980.9K666.0K-20.0K-361.0K1.33M5.00K-28.0K
Cash from financing17.4M13.2M10.1M6.00M7.25M5.96M6.26M6.00M13.3M7.25M
Share buybacks12.5M10.0M0
Change in cash-616.0K-3.95M7.09M61.0K57.0K-1.88M-4.25M-668.0K7.12M-1.20M

Open Financials

Filings

FilingDateTypeFiled with
8-K · Current reportNov 12, 2026ResultsSEC
10-Q · Quarterly reportNov 12, 2026Quarterly reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 3, 2026Big-stake noticeSEC
8-K · Current reportOct 9, 2026Current reportSEC
8-K · Current reportSep 9, 2026Current reportSEC
EFFECT · Notice that a registration is effectiveSep 1, 2026Other filingsSEC
8-K · Current reportAug 26, 2026Material contractSEC
S-1 · Registration statementAug 24, 2026Offer documentSEC
S-8 · Registration statement for employee plansAug 13, 2026Offer documentSEC
8-K · Current reportAug 13, 2026ResultsSEC
Show 200 filings
FilingDateTypeFiled with
10-Q · Quarterly reportAug 13, 2026Quarterly reportSEC
4 · Change in ownershipJul 23, 2026Insider tradeSEC
3 · Initial statement of ownershipJul 23, 2026Insider tradeSEC
8-K · Current reportJul 23, 2026Management or board changeSEC
8-K · Current reportJul 22, 2026Management or board changeSEC
SCHEDULE 13D/A · Big-stake notice, amendedJul 22, 2026Big-stake noticeSEC
4 · Change in ownershipJul 9, 2026Insider tradeSEC
8-K · Current reportJun 24, 2026Meeting outcomeSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
4 · Change in ownershipJun 15, 2026Insider tradeSEC
EFFECT · Notice that a registration is effectiveJun 4, 2026Other filingsSEC
CORRESP · Letter to the SECJun 1, 2026Other filingsSEC
UPLOAD · Letter from the SECMay 29, 2026Other filingsSEC
4 · Change in ownershipMay 27, 2026Insider tradeSEC
4 · Change in ownershipMay 26, 2026Insider tradeSEC
4 · Change in ownershipMay 26, 2026Insider tradeSEC
4 · Change in ownershipMay 26, 2026Insider tradeSEC
4 · Change in ownershipMay 26, 2026Insider tradeSEC
4 · Change in ownershipMay 26, 2026Insider tradeSEC
4 · Change in ownershipMay 22, 2026Insider tradeSEC
S-3 · Registration statementMay 22, 2026Offer documentSEC
8-K · Current reportMay 14, 2026ResultsSEC
10-Q · Quarterly reportMay 14, 2026Quarterly reportSEC
SCHEDULE 13G · Big-stake noticeMay 4, 2026Big-stake noticeSEC
DEFA14A · Additional proxy materialApr 28, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 27, 2026Meeting noticeSEC
8-K · Current reportApr 21, 2026Management or board changeSEC
4 · Change in ownershipApr 21, 2026Insider tradeSEC
4 · Change in ownershipApr 21, 2026Insider tradeSEC
PRE 14A · Preliminary proxy statementApr 17, 2026Meeting noticeSEC
10-K/A · Annual report, amendedMar 27, 2026Annual reportSEC
S-8 · Registration statement for employee plansMar 25, 2026Offer documentSEC
8-K · Current reportMar 25, 2026ResultsSEC
10-K · Annual reportMar 25, 2026Annual reportSEC
4 · Change in ownershipMar 24, 2026Insider tradeSEC
8-K · Current reportMar 23, 2026Material contractSEC
4 · Change in ownershipMar 20, 2026Insider tradeSEC
4 · Change in ownershipFeb 17, 2026Insider tradeSEC
4 · Change in ownershipFeb 17, 2026Insider tradeSEC
4 · Change in ownershipFeb 17, 2026Insider tradeSEC
4 · Change in ownershipFeb 17, 2026Insider tradeSEC
EFFECT · Notice that a registration is effectiveFeb 17, 2026Other filingsSEC
CORRESP · Letter to the SECFeb 11, 2026Other filingsSEC
UPLOAD · Letter from the SECFeb 9, 2026Other filingsSEC
4 · Change in ownershipFeb 3, 2026Insider tradeSEC
S-3 · Registration statementJan 30, 2026Offer documentSEC
4 · Change in ownershipJan 29, 2026Insider tradeSEC
8-K · Current reportJan 28, 2026Current reportSEC
4 · Change in ownershipJan 23, 2026Insider tradeSEC
4 · Change in ownershipJan 21, 2026Insider tradeSEC
144 · Notice of proposed saleJan 20, 2026Other filingsSEC
8-K · Current reportJan 15, 2026Current reportSEC
4 · Change in ownershipJan 14, 2026Insider tradeSEC
4 · Change in ownershipJan 9, 2026Insider tradeSEC
4 · Change in ownershipDec 29, 2025Insider tradeSEC
4 · Change in ownershipDec 23, 2025Insider tradeSEC
4 · Change in ownershipDec 17, 2025Insider tradeSEC
4 · Change in ownershipDec 16, 2025Insider tradeSEC
4 · Change in ownershipDec 12, 2025Insider tradeSEC
4 · Change in ownershipDec 11, 2025Insider tradeSEC
8-K · Current reportDec 10, 2025Current reportSEC
4 · Change in ownershipDec 4, 2025Insider tradeSEC
4 · Change in ownershipNov 26, 2025Insider tradeSEC
4 · Change in ownershipNov 25, 2025Insider tradeSEC
4 · Change in ownershipNov 19, 2025Insider tradeSEC
8-K · Current reportNov 13, 2025ResultsSEC
10-Q · Quarterly reportNov 13, 2025Quarterly reportSEC
4 · Change in ownershipNov 12, 2025Insider tradeSEC
8-K · Current reportNov 12, 2025Meeting outcomeSEC
4 · Change in ownershipNov 10, 2025Insider tradeSEC
4 · Change in ownershipNov 10, 2025Insider tradeSEC
4 · Change in ownershipNov 10, 2025Insider tradeSEC
4 · Change in ownershipNov 10, 2025Insider tradeSEC
4 · Change in ownershipNov 10, 2025Insider tradeSEC
4 · Change in ownershipNov 6, 2025Insider tradeSEC
4 · Change in ownershipNov 5, 2025Insider tradeSEC
8-K · Current reportNov 3, 2025Current reportSEC
4 · Change in ownershipOct 29, 2025Insider tradeSEC
4 · Change in ownershipOct 28, 2025Insider tradeSEC
DEFR14AOct 27, 2025Meeting noticeSEC
4 · Change in ownershipOct 21, 2025Insider tradeSEC
144 · Notice of proposed saleOct 14, 2025Other filingsSEC
4 · Change in ownershipOct 14, 2025Insider tradeSEC
8-K · Current reportOct 6, 2025Current reportSEC
DEFA14A · Additional proxy materialSep 26, 2025Meeting noticeSEC
DEF 14A · Proxy statementSep 26, 2025Meeting noticeSEC
PRE 14A · Preliminary proxy statementSep 15, 2025Meeting noticeSEC
8-K · Current reportSep 15, 2025Material contractSEC
8-K · Current reportSep 9, 2025Current reportSEC
4 · Change in ownershipAug 27, 2025Insider tradeSEC
8-K · Current reportAug 25, 2025Current reportSEC
8-K · Current reportAug 22, 2025Current reportSEC
4 · Change in ownershipAug 20, 2025Insider tradeSEC
4 · Change in ownershipAug 14, 2025Insider tradeSEC
8-K · Current reportAug 11, 2025ResultsSEC
10-Q · Quarterly reportAug 11, 2025Quarterly reportSEC
4 · Change in ownershipAug 6, 2025Insider tradeSEC
4 · Change in ownershipJul 30, 2025Insider tradeSEC
4 · Change in ownershipJul 29, 2025Insider tradeSEC
8-K · Current reportJul 29, 2025Current reportSEC
4 · Change in ownershipJul 22, 2025Insider tradeSEC
4 · Change in ownershipJul 17, 2025Insider tradeSEC
4 · Change in ownershipJul 9, 2025Insider tradeSEC
4 · Change in ownershipJul 2, 2025Insider tradeSEC
8-K · Current reportJul 1, 2025Current reportSEC
144 · Notice of proposed saleJun 30, 2025Other filingsSEC
4 · Change in ownershipJun 17, 2025Insider tradeSEC
3 · Initial statement of ownershipJun 17, 2025Insider tradeSEC
8-K · Current reportMay 22, 2025Management or board changeSEC
8-K · Current reportMay 8, 2025ResultsSEC
10-Q · Quarterly reportMay 8, 2025Quarterly reportSEC
8-K · Current reportApr 29, 2025Material contractSEC
EFFECT · Notice that a registration is effectiveApr 29, 2025Other filingsSEC
424B5 · ProspectusApr 25, 2025Offer documentSEC
CORRESP · Letter to the SECApr 24, 2025Other filingsSEC
UPLOAD · Letter from the SECApr 23, 2025Other filingsSEC
S-3 · Registration statementApr 17, 2025Offer documentSEC
8-K · Current reportApr 15, 2025Current reportSEC
8-K · Current reportApr 14, 2025Material contractSEC
EFFECT · Notice that a registration is effectiveApr 11, 2025Other filingsSEC
4 · Change in ownershipApr 10, 2025Insider tradeSEC
4 · Change in ownershipApr 10, 2025Insider tradeSEC
CORRESP · Letter to the SECApr 8, 2025Other filingsSEC
UPLOAD · Letter from the SECApr 7, 2025Other filingsSEC
8-K · Current reportApr 7, 2025Current reportSEC
S-8 · Registration statement for employee plansApr 2, 2025Offer documentSEC
S-3 · Registration statementApr 2, 2025Offer documentSEC
4 · Change in ownershipApr 1, 2025Insider tradeSEC
424B3 · ProspectusMar 25, 2025Offer documentSEC
POS EXMar 24, 2025Other filingsSEC
8-K · Current reportMar 24, 2025ResultsSEC
10-K · Annual reportMar 24, 2025Annual reportSEC
8-K · Current reportMar 24, 2025Current reportSEC
4 · Change in ownershipFeb 13, 2025Insider tradeSEC
3 · Initial statement of ownershipFeb 13, 2025Insider tradeSEC
8-K · Current reportFeb 12, 2025Management or board changeSEC
8-K · Current reportFeb 3, 2025Current reportSEC
4 · Change in ownershipFeb 3, 2025Insider tradeSEC
4 · Change in ownershipJan 15, 2025Insider tradeSEC
3 · Initial statement of ownershipJan 15, 2025Insider tradeSEC
8-K · Current reportJan 14, 2025Management or board changeSEC
8-K · Current reportJan 6, 2025ResultsSEC
8-K · Current reportDec 23, 2024Acquisition or disposalSEC
4 · Change in ownershipDec 19, 2024Insider tradeSEC
8-K · Current reportDec 18, 2024Management or board changeSEC
8-K · Current reportDec 11, 2024Current reportSEC
SC 13D/A · Big-stake notice, amendedDec 9, 2024Big-stake noticeSEC
8-K · Current reportDec 2, 2024Material contractSEC
424B3 · ProspectusNov 22, 2024Offer documentSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
8-K · Current reportNov 12, 2024ResultsSEC
10-Q · Quarterly reportNov 12, 2024Quarterly reportSEC
ARS · Annual report to shareholdersNov 6, 2024Annual reportSEC
DEFA14A · Additional proxy materialNov 6, 2024Meeting noticeSEC
DEF 14A · Proxy statementNov 6, 2024Meeting noticeSEC
DEFC14ANov 1, 2024Other filingsSEC
8-K · Current reportOct 2, 2024Current reportSEC
4 · Change in ownershipSep 24, 2024Insider tradeSEC
4 · Change in ownershipSep 20, 2024Insider tradeSEC
4 · Change in ownershipSep 16, 2024Insider tradeSEC
8-K · Current reportSep 12, 2024Management or board changeSEC
4 · Change in ownershipSep 11, 2024Insider tradeSEC
8-K · Current reportSep 4, 2024Current reportSEC
S-8 · Registration statement for employee plansAug 23, 2024Offer documentSEC
4 · Change in ownershipAug 22, 2024Insider tradeSEC
4 · Change in ownershipAug 20, 2024Insider tradeSEC
3 · Initial statement of ownershipAug 20, 2024Insider tradeSEC
4 · Change in ownershipAug 20, 2024Insider tradeSEC
4 · Change in ownershipAug 19, 2024Insider tradeSEC
4 · Change in ownershipAug 16, 2024Insider tradeSEC
8-K · Current reportAug 15, 2024Management or board changeSEC
8-K · Current reportAug 9, 2024ResultsSEC
10-Q · Quarterly reportAug 9, 2024Quarterly reportSEC
8-K · Current reportJul 29, 2024Current reportSEC
8-K · Current reportJul 18, 2024Management or board changeSEC
4 · Change in ownershipJul 17, 2024Insider tradeSEC
3 · Initial statement of ownershipJul 17, 2024Insider tradeSEC
8-K · Current reportJul 12, 2024Management or board changeSEC
EFFECT · Notice that a registration is effectiveJul 10, 2024Other filingsSEC
SC 13D/A · Big-stake notice, amendedJul 5, 2024Big-stake noticeSEC
CORRESP · Letter to the SECJul 5, 2024Other filingsSEC
S-1/A · Registration statement, amendedJul 3, 2024Offer documentSEC
4 · Change in ownershipJun 27, 2024Insider tradeSEC
S-1/A · Registration statement, amendedJun 14, 2024Offer documentSEC
S-8 · Registration statement for employee plansJun 14, 2024Offer documentSEC
8-K · Current reportJun 10, 2024Current reportSEC

This page holds 200 of 521 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Serina Therapeutics, Inc.’s releases · as of Nov 13, 2025

Common shares
25,400,473
Fully diluted
25,400,473

Fully diluted

LineShares
Common shares25,400,473

Warrants and options

Lot
Warrants · US$5.44 · expiry not stated

Share count over time

CountShares
Nov 22, 202625,400,473

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Sio Capital Management, LLC2M7.5%US$4MSep 30, 2026
Vanguard205K0.77%US$409KSep 30, 2026
Ashton Thomas Private Wealth, LLC88,8880.33%US$178KSep 30, 2026
Waverly Advisors, LLC67,4920.25%US$135KSep 30, 2026
Geode Capital32,2030.12%US$64,407Sep 30, 2026
Virtu Financial LLC22,5960.09%US$45,000Sep 30, 2026
Northern Trust20,7710.08%US$41,542Sep 30, 2026
Avidian Wealth Enterprises, LLC18,8000.07%US$37,600Sep 30, 2026
State Street12,7580.05%US$25,516Sep 30, 2026
Keel Point, LLC10,8090.04%US$21,618Sep 30, 2026
All 27 holders
HolderSharesOf the companyValueAs of
Citigroup Inc5,2300.02%US$10,460Sep 30, 2026
Caitong International Asset Management Co., Ltd3,6820.01%US$7,364Sep 30, 2026
Wells Fargo3,6110.01%US$7,222Sep 30, 2026
Tower Research Capital LLC (TRC)3,0750.01%US$6,150Sep 30, 2026
BlackRock2,378<0.01%US$4,756Sep 30, 2026
Osaic Holdings, Inc.2,002<0.01%US$4,004Sep 30, 2026
RBC1,000<0.01%US$2,000Sep 30, 2026
Morgan Stanley608<0.01%US$1,216Sep 30, 2026
Piscataqua Savings Bank28<0.01%US$56Sep 30, 2026
Pacifica Partners Inc.8<0.01%US$16Sep 30, 2026
Albion Financial Group8<0.01%US$16Sep 30, 2026
UBS5<0.01%US$10Sep 30, 2026
Barclays4<0.01%US$8Sep 30, 2026
JPMorgan3<0.01%US$6Sep 30, 2026
Rockefeller Capital Management L.P.2<0.01%US$4Sep 30, 2026
BNP Paribas2<0.01%US$4Sep 30, 2026
Farther Finance Advisors, LLC1<0.01%US$2Sep 30, 2026

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund126K0.47%US$244KJun 30, 2026
Fidelity Extended Market Index Fund45,2480.17%US$83,256May 31, 2026
Vanguard Extended Market Index Fund33,3310.13%US$64,662Jun 30, 2026
Fidelity Series Total Market Index Fund4,7390.02%US$8,720May 31, 2026
Fidelity Total Market Index Fund2,592<0.01%US$4,769May 31, 2026
Ultra-Small Company Market Fund2,495<0.01%US$4,840Jun 30, 2026

Insider trades

TradeTradeSharesPriceValueDate
Brannan Stephen K.
Director
Buy1,000USD 2.03US$2,030Jul 7, 2026
Wilson Karen J
Director
Buy5,000USD 1.77US$8,850Jun 12, 2026
Wilson Karen J
Director
Buy5,100USD 1.75US$8,925Jun 11, 2026
Venkatesan Jay
Director
Buy589USD 1.78US$1,048May 22, 2026
Wilson Karen J
Director
Buy10,000USD 1.93US$19,300May 22, 2026
Wilson Karen J
Director
Buy10,000USD 1.77US$17,700May 21, 2026
Marshall Richard Peter
Director
Buy12,183USD 1.65US$20,102May 19, 2026

Big stakes

StakeStakeSharesDateFiling
Sio Capital Management, LLC7.87%2MSep 30, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Annalisa Jenkins
Other companies: Skye Bioscience, Inc. (Director · Since at least Feb 29, 2024); Mereo BioPharma Group plc (Director · Since at least Jan 1, 2024); COMPASS Pathways Plc (Director · Since at least Jan 1, 2022); Tectonic Therapeutic, Inc. (Director · Jun 20, 2018 – Jun 6, 2023 · Past); Dimension Therapeutics (President and CEO, Director · Oct 21, 2015 – Nov 7, 2017 · Past); Ardelyx, Inc. (Director · Apr 20, 2015 – Jun 13, 2019 · Past)
Director · Nov 27, 2018 – Jun 21, 2021 · Past
Russell Skibsted
Other companies: Processa Pharmaceuticals, Inc. (Chief Financial Officer · Since at least Jul 16, 2024); Aeolus Pharmaceuticals Inc (Chief Financial Officer · Since at least May 23, 2012); Alimera Sciences Inc (Chief Financial Officer & SVP · Jan 9, 2023 – Nov 21, 2023 · Past); Rockwell Medical, Inc. (See Remarks · Sep 15, 2020 – Sep 9, 2022 · Past); Insight Molecular Diagnostics Inc. (Chief Financial Officer · Dec 30, 2015 – Dec 30, 2015 · Past); Lineage Cell Therapeutics, Inc. (Chief Financial Officer · Nov 16, 2015 – Dec 18, 2018 · Past)
Chief Financial Officer · Nov 27, 2018 – Dec 31, 2018 · Past
Karen J. Wilson
Other companies: Connect Biopharma Holdings Limited (Board Director · Since at least Mar 16, 2026); LAVA Therapeutics NV (Director · Since at least Jan 1, 2025); Elicio Therapeutics, Inc. (Director · Since at least Feb 4, 2021); Vaxart, Inc. (Director · Aug 25, 2020 – Jun 16, 2021 · Past); Jazz Pharmaceuticals plc (SVP, Finance & PAO · Mar 9, 2011 – Mar 5, 2019 · Past)
Director · Since at least Jan 14, 2025
Michael D West
Other companies: Insight Molecular Diagnostics Inc. (Director · Dec 30, 2015 – Feb 16, 2016 · Past); Asterias Biotherapeutics Inc (VP of Technology Integration, Director · Feb 13, 2015 – Feb 13, 2015 · Past); Ocata Therapeutics Inc (Director · Oct 9, 2007 – Oct 9, 2007 · Past); Lineage Cell Therapeutics, Inc. (Co-Chief Executive Officer, Director · Dec 31, 2005 – Sep 17, 2018 · Past)
Chief Executive Officer · Nov 27, 2018 – Mar 11, 2023 · Past
Jay Venkatesan
Other companies: Elicio Therapeutics, Inc. (Director · Since at least May 20, 2022); Alpine Immune Sciences Inc (Director · Jul 15, 2022 – Jul 15, 2022 · Past)
Director · Since at least Feb 12, 2025
Michael H. Mulroy
Other companies: Lineage Cell Therapeutics, Inc. (Chairman of the Board · Since at least Jul 1, 2016); Asterias Biotherapeutics Inc (President and CEO, Director · Jun 26, 2017 – Mar 1, 2019 · Past)
Director · Nov 27, 2018 – Mar 11, 2019 · Past
Simba Gill
Other companies: Foghorn Therapeutics Inc. (Executive Chairman, Serina Therapeutics and Sensorium Therapeutics · Since at least Oct 22, 2020); Evelo Biosciences, Inc. (President & CEO, Director · May 8, 2018 – Nov 7, 2023 · Past)
Director · Since at least Apr 12, 2024
Farrell Simon
Other companies: Trevi Therapeutics, Inc. (Chief Commercial Officer · Since at least Feb 16, 2023)
Director · Since at least Jul 22, 2026
Hal Sternberg
Other companies: Lineage Cell Therapeutics, Inc. (Vice President · Dec 31, 2008 – Dec 31, 2009 · Past)
Vice President-Research · Nov 27, 2018 – Jun 4, 2021 · Past
Andrea Eun Jae ParkChief Financial Officer · Jun 4, 2021 – Jun 4, 2021 · Past
All 26 people
PersonSeat
Greg CurhanCFO · Since at least Nov 4, 2026
Gregory BaileyCo-Chairman · Since at least Jun 22, 2026
Jean-Christophe RenondinDirector · Aug 9, 2023 – Aug 9, 2023 · Past
Joanne M HackettDirector · Dec 29, 2021 – Feb 2, 2022 · Past
Joshua ThomasVP, Head of Chemistry · Since at least Dec 11, 2025
Michael H MayDirector · Aug 5, 2019 – Jun 21, 2021 · Past
Randall MoreadithChief Development Officer · Since at least Mar 26, 2024
Remy GrossDirector · Mar 26, 2024 – Apr 1, 2024 · Past
Richard MarshallDirector · Since at least Mar 26, 2024
Srini TenjarlaChief Technical Operations Officer · Since at least Nov 4, 2026
Stephen K BrannanDirector · Since at least Jul 7, 2026
Steve BrannanDirector · Since at least May 22, 2025
Steve LedgerCEO & Director · Since at least May 27, 2026
Steven A LedgerChief Executive Officer, Director · Since at least Mar 26, 2024
Steven MintzDirector · Jan 8, 2024 – Sep 12, 2024 · Past
Tacey ViegasCOO and Secretary · Mar 26, 2024 – Mar 26, 2024 · Past

Open People

Log in to ask 6ix AI your own questions about Serina Therapeutics, Inc.